Advisory Committee on the Medical Uses of Isotopes Renewal Notice, 9760-9761 [2018-04610]

Download as PDF 9760 Federal Register / Vol. 83, No. 45 / Wednesday, March 7, 2018 / Notices for the public-interest determination is left to the discretion of the court, with the recognition that the court’s ‘‘scope of review remains sharply proscribed by precedent and the nature of Tunney Act proceedings.’’ SBC Commc’ns, 489 F. Supp. 2d at 11.3 A court can make its public-interest determination based on the competitive impact statement and response to public comments alone. U.S. Airways, 38 F. Supp. 3d at 76. VIII. DETERMINATIVE DOCUMENTS There are no determinative materials or documents within the meaning of the APPA that were considered by the United States in formulating the proposed Final Judgment. Dated: February 27, 2018 Respectfully submitted, FOR PLAINTIFF UNITED STATES OF AMERICA: Peter Caplan (P–30643), Assistant United States Attorney, U.S. Attorney’s Office, Eastern District of Michigan, 211 W. Fort Street, Suite 2001, Detroit, Michigan 48226, (313) 226–9784, peter.caplan@usdoj.gov. \s\Katrina Rouse Katrina Rouse (D.C. Bar No. 1013035), Garrett Liskey, Andrew Robinson, Jill Maguire, Healthcare & Consumer Products Section, Antitrust Division, U.S. Department of Justice, 450 Fifth St., NW, Washington, DC 20530, (415) 934–5346, Katrina.Rouse@ usdoj.gov. Certificate of Service daltland on DSKBBV9HB2PROD with NOTICES I hereby certify that on February 27, 2018, I electronically filed the foregoing paper with the Clerk of Court using the ECF system, which will send notification of the filing to the counsel of record for all parties for civil action 5:15-cv-12311–JEL–DRG, and I hereby certify that there are no individuals entitled to notice who are non-ECF participants. \s\Garrett Liskey Garrett Liskey (D.C. Bar No. 1000937) Antitrust Division, Healthcare and Consumer Products Section, U.S. Department of Justice, 3 See United States v. Enova Corp., 107 F. Supp. 2d 10, 17 (D.D.C. 2000) (noting that the ‘‘Tunney Act expressly allows the court to make its public interest determination on the basis of the competitive impact statement and response to comments alone’’); United States v. Mid-Am. Dairymen, Inc., No. 73-CV-681-W-1, 1977-1 Trade Cas. (CCH) ¶ 61,508, at 71,980, *22 (W.D. Mo. 1977) (‘‘Absent a showing of corrupt failure of the government to discharge its duty, the Court, in making its public interest finding, should . . . carefully consider the explanations of the government in the competitive impact statement and its responses to comments in order to determine whether those explanations are reasonable under the circumstances.’’); S. Rep. No. 93-298, at 6 (1973) (‘‘Where the public interest can be meaningfully evaluated simply on the basis of briefs and oral arguments, that is the approach that should be utilized.’’). VerDate Sep<11>2014 18:46 Mar 06, 2018 Jkt 244001 450 Fifth St., NW, Washington, DC 20530, (202) 598–2849, Garrett.Liskey@usdoj.gov. [FR Doc. 2018–04593 Filed 3–6–18; 8:45 am] BILLING CODE 4410–11–P DEPARTMENT OF JUSTICE Notice of Lodging of Proposed Consent Decree Under the Comprehensive Environmental Response, Compensation and Liabiilty Act On February 22, 2018, the Department of Justice lodged a proposed Consent Decree with the United States District Court for the Southern District of New York in a lawsuit entitled United States v. Steel of West Virginia, Civil Action No. 18–1661. In this action the United States seeks, as provided under the Comprehensive Environmental Response, Compensation and Liability Act, recovery of response costs from Steel of West Virginia regarding the Port Refinery Superfund Site (‘‘Site’’) in the Village of Rye Brook, New York. The proposed Consent Decree resolves the United States’ claims and requires Steel of West Virginia to pay $35,829 in reimbursement of the United States’ past response costs regarding the Site. The publication of this notice opens a public comment period on the proposed Consent Decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and should refer to United States v. Steel of West Virginia, Civil Action No. 18–1661, D.J. Ref. 90–11–3–1142/4. All comments must be submitted no later than 30 days after the publication date of this notice. Comments may be submitted either by email or by mail: To submit comments: Send them to: By e-mail ...... pubcomment-ees.enrd@ usdoj.gov. Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044–7611. By mail ......... During the public comment period, the Consent Decree may be examined and downloaded at this Justice Department website: https:// www.usdoj.gov/enrd/Consent_ Decrees.html. We will provide a paper copy of the Consent Decree upon written request and payment of reproduction costs. Please email your request and payment to: Consent Decree Library, U.S. DOJ–ENRD, P.O. Box 7611, Washington, DC 20044–7611. PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 Please enclose a check or money order for $4.25 (25 cents per page reproduction cost) payable to the United States Treasury. Robert E. Maher, Jr., Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division. [FR Doc. 2018–04570 Filed 3–6–18; 8:45 am] BILLING CODE 4410–15–P NUCLEAR REGULATORY COMMISSION Advisory Committee on the Medical Uses of Isotopes Renewal Notice Nuclear Regulatory Commission. ACTION: This notice is to announce the renewal of the Advisory Committee on the Medical Uses of Isotopes (ACMUI) for a period of 2 years. AGENCY: The U.S. Nuclear Regulatory Commission (NRC) has determined that the renewal of the Charter for the Advisory Committee on the Medical Uses of Isotopes for the 2 year period commencing on March 1, 2018, is in the public interest, in connection with duties imposed on the Commission by law. This action is being taken in accordance with the Federal Advisory Committee Act, after consultation with the Committee Management Secretariat, General Services Administration. The purpose of the ACMUI is to provide advice to NRC on policy and technical issues that arise in regulating the medical use of byproduct material for diagnosis and therapy. Responsibilities include providing guidance and comments on current and proposed NRC regulations and regulatory guidance concerning medical use; evaluating certain non-routine uses of byproduct material for medical use; and evaluating training and experience of proposed authorized users. The members are involved in preliminary discussions of major issues in determining the need for changes in NRC policy and regulation to ensure the continued safe use of byproduct material. Each member provides technical assistance in his/her specific area(s) of expertise, particularly with respect to emerging technologies. Members also provide guidance as to NRC’s role in relation to the responsibilities of other Federal agencies as well as of various professional organizations and boards. Members of this Committee have demonstrated professional SUPPLEMENTARY INFORMATION: E:\FR\FM\07MRN1.SGM 07MRN1 Federal Register / Vol. 83, No. 45 / Wednesday, March 7, 2018 / Notices qualifications and expertise in both scientific and non-scientific disciplines including nuclear medicine; nuclear cardiology; radiation therapy; medical physics; nuclear pharmacy; State medical regulation; patient’s rights and care; health care administration; and Food and Drug Administration regulation. FOR FURTHER INFORMATION CONTACT: Sophie Holiday, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, DC 20555; Telephone (301) 415–7865; email Sophie.Holiday@ nrc.gov. Dated at Rockville, Maryland, this 1st day of March, 2018. For the Nuclear Regulatory Commission. Russell E. Chazell, Federal Advisory Committee Management Officer. [FR Doc. 2018–04610 Filed 3–6–18; 8:45 am] BILLING CODE 7590–01–P POSTAL REGULATORY COMMISSION [Docket No. CP2018–174] New Postal Product Postal Regulatory Commission. Notice. AGENCY: ACTION: The Commission is noticing a recent Postal Service filing for the Commission’s consideration concerning negotiated service agreements. This notice informs the public of the filing, invites public comment, and takes other administrative steps. DATES: Comments are due: March 9, 2018. ADDRESSES: Submit comments electronically via the Commission’s Filing Online system at https:// www.prc.gov. Those who cannot submit comments electronically should contact the person identified in the FOR FURTHER INFORMATION CONTACT section by telephone for advice on filing alternatives. FOR FURTHER INFORMATION CONTACT: David A. Trissell, General Counsel, at 202–789–6820. SUPPLEMENTARY INFORMATION: SUMMARY: daltland on DSKBBV9HB2PROD with NOTICES Table of Contents I. Introduction II. Docketed Proceeding(s) I. Introduction The Commission gives notice that the Postal Service filed request(s) for the Commission to consider matters related to negotiated service agreement(s). The request(s) may propose the addition or VerDate Sep<11>2014 17:30 Mar 06, 2018 Jkt 244001 removal of a negotiated service agreement from the market dominant or the competitive product list, or the modification of an existing product currently appearing on the market dominant or the competitive product list. Section II identifies the docket number(s) associated with each Postal Service request, the title of each Postal Service request, the request’s acceptance date, and the authority cited by the Postal Service for each request. For each request, the Commission appoints an officer of the Commission to represent the interests of the general public in the proceeding, pursuant to 39 U.S.C. 505 (Public Representative). Section II also establishes comment deadline(s) pertaining to each request. The public portions of the Postal Service’s request(s) can be accessed via the Commission’s website (https:// www.prc.gov). Non-public portions of the Postal Service’s request(s), if any, can be accessed through compliance with the requirements of 39 CFR 3007.40. The Commission invites comments on whether the Postal Service’s request(s) in the captioned docket(s) are consistent with the policies of title 39. For request(s) that the Postal Service states concern market dominant product(s), applicable statutory and regulatory requirements include 39 U.S.C. 3622, 39 U.S.C. 3642, 39 CFR part 3010, and 39 CFR part 3020, subpart B. For request(s) that the Postal Service states concern competitive product(s), applicable statutory and regulatory requirements include 39 U.S.C. 3632, 39 U.S.C. 3633, 39 U.S.C. 3642, 39 CFR part 3015, and 39 CFR part 3020, subpart B. Comment deadline(s) for each request appear in section II. II. Docketed Proceeding(s) 1. Docket No(s).: CP2018–174; Filing Title: Notice of United States Postal Service of Filing a Functionally Equivalent Global Expedited Package Services 7 Negotiated Service Agreement and Application for NonPublic Treatment of Materials Filed Under Seal; Filing Acceptance Date: March 1, 2018; Filing Authority: 39 CFR 3015.5; Public Representative: Timothy J. Schwuchow; Comments Due: March 9, 2018. This Notice will be published in the Federal Register. Stacy L. Ruble, Secretary. [FR Doc. 2018–04615 Filed 3–6–18; 8:45 am] SECURITIES AND EXCHANGE COMMISSION [Release No. 34–82801; File No. SR–OCC– 2017–022] Self-Regulatory Organizations; The Options Clearing Corporation; Order Instituting Proceedings To Determine Whether To Approve or Disapprove Proposed Rule Change Related to The Options Clearing Corporation’s Margin Methodology March 2, 2018. I. Introduction On November 13, 2017, The Options Clearing Corporation (‘‘OCC’’) filed with the Securities and Exchange Commission (‘‘Commission’’) the proposed rule change SR–OCC–2017– 022 (‘‘Proposed Rule Change’’) pursuant to Section 19(b) of the Securities Exchange Act of 1934 (‘‘Act’’),1 and Rule 19b–4 thereunder.2 The Proposed Rule Change was published for comment in the Federal Register on December 4, 2017.3 On January 18, 2018, the Commission designated a longer period of time for Commission action on the Proposed Rule Change.4 As of February 20, 2018,5 the Commission has received one comment letter on the proposal contained in the Advance Notice.6 The Commission is 1 15 U.S.C. 78s(b)(1). CFR 240.19b–4. 3 Securities Exchange Act Release No. 82161 (Nov. 28, 2017), 82 FR 57306 (Dec. 4, 2017) (File No. SR–OCC–2017–022) (‘‘Notice’’). On November 13, 2017, OCC also filed a related advance notice (SR–OCC–2017–811) with the Commission pursuant to Section 806(e)(1) of Title VIII of the Dodd-Frank Wall Street Reform and Consumer Protection Act, entitled the Payment, Clearing, and Settlement Supervision Act of 2010 and Rule 19b– 4(n)(1)(i) under the Act (‘‘Advance Notice’’). 12 U.S.C. 5465(e)(1) and 17 CFR 240.19b–4(n)(1)(i), respectively. The Advance Notice was published in the Federal Register on December 27, 2017. Securities Exchange Act Release No. 82371 (Dec. 20, 2017), 82 FR 61354 (Dec. 27, 2017) (SR–OCC– 2017–811). The Financial Stability Oversight Council designated OCC a systemically important financial market utility on July 18, 2012. See Financial Stability Oversight Council 2012 Annual Report, Appendix A, available at https://www.treasury.gov/ initiatives/fsoc/Documents/ 2012%20Annual%20Report.pdf. Therefore, OCC is required to comply with the Payment, Clearing and Settlement Supervision Act and file advance notices with the Commission. See 12 U.S.C. 5465(e). 4 Securities Exchange Act Release No. 82534 (Jan. 18, 2018), 83 FR 3376 (Jan. 24, 2018) (File No. SR– OCC–2017–022). 5 The comment period closed on December 26, 2017. 6 See letter from Michael Kitlas, dated November 28, 2017, to Eduardo A. Aleman, Assistant Secretary, Commission, available at https:// www.sec.gov/comments/sr-occ-2017-022/ occ2017022.htm (‘‘Kitlas Letter’’). After reviewing 2 17 Continued BILLING CODE 7710–FW–P PO 00000 Frm 00038 Fmt 4703 9761 Sfmt 4703 E:\FR\FM\07MRN1.SGM 07MRN1

Agencies

[Federal Register Volume 83, Number 45 (Wednesday, March 7, 2018)]
[Notices]
[Pages 9760-9761]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-04610]


=======================================================================
-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION


Advisory Committee on the Medical Uses of Isotopes Renewal Notice

AGENCY: Nuclear Regulatory Commission.

ACTION: This notice is to announce the renewal of the Advisory 
Committee on the Medical Uses of Isotopes (ACMUI) for a period of 2 
years.

-----------------------------------------------------------------------

SUPPLEMENTARY INFORMATION: The U.S. Nuclear Regulatory Commission (NRC) 
has determined that the renewal of the Charter for the Advisory 
Committee on the Medical Uses of Isotopes for the 2 year period 
commencing on March 1, 2018, is in the public interest, in connection 
with duties imposed on the Commission by law. This action is being 
taken in accordance with the Federal Advisory Committee Act, after 
consultation with the Committee Management Secretariat, General 
Services Administration.
    The purpose of the ACMUI is to provide advice to NRC on policy and 
technical issues that arise in regulating the medical use of byproduct 
material for diagnosis and therapy. Responsibilities include providing 
guidance and comments on current and proposed NRC regulations and 
regulatory guidance concerning medical use; evaluating certain non-
routine uses of byproduct material for medical use; and evaluating 
training and experience of proposed authorized users. The members are 
involved in preliminary discussions of major issues in determining the 
need for changes in NRC policy and regulation to ensure the continued 
safe use of byproduct material. Each member provides technical 
assistance in his/her specific area(s) of expertise, particularly with 
respect to emerging technologies. Members also provide guidance as to 
NRC's role in relation to the responsibilities of other Federal 
agencies as well as of various professional organizations and boards.
    Members of this Committee have demonstrated professional

[[Page 9761]]

qualifications and expertise in both scientific and non-scientific 
disciplines including nuclear medicine; nuclear cardiology; radiation 
therapy; medical physics; nuclear pharmacy; State medical regulation; 
patient's rights and care; health care administration; and Food and 
Drug Administration regulation.

FOR FURTHER INFORMATION CONTACT: Sophie Holiday, Office of Nuclear 
Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, 
Washington, DC 20555; Telephone (301) 415-7865; email 
[email protected].

    Dated at Rockville, Maryland, this 1st day of March, 2018.

    For the Nuclear Regulatory Commission.
Russell E. Chazell,
Federal Advisory Committee Management Officer.
[FR Doc. 2018-04610 Filed 3-6-18; 8:45 am]
 BILLING CODE 7590-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.